Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

Company to invest in further research to strengthen clinical evidence ahead of medium-term U.S. launch with no further FDA approvals needed PERTH, Australia, Nov. 20, 2025 /PRNewswire/ -- Orthocell ...

EDAP TMS reported Q2 2023 revenues of $15.52 million, a 0.9% YoY growth that missed estimates. In Q2 2023, HIFU’s total revenue growth stood at 63.6% (YoY). The procedure growth of Focal One shot up ...

Cigna Expands Commercial and Medicare AdvantageCoverage to Include Mdxhealth’s Select mdx for Prostate Cancer Test Expansion of coverage with Cigna now includes full menu of Company’s precision ...

Although the use of tissue-based gene expression testing for prostate cancer was found to be “highly variable in the United States at the regional level,” distinct regional trajectories of commercial ...

Timing and uptake of germline testing in patients with somatic BRCA1/2 pathogenic or likely pathogenic variants in solid tumors: A real-world study from community oncology practices. Identifying ...

This promising new application for Remplir can potentially reduce post-surgical complications from peripheral nerve injury, representing a globally significant commercial opportunity for the Company.